MedDataX Logo

Complement Regulatory Proteins Expression and Clinical Response in Rheumatoid Arthritis (RA) Patients Treated With Rituximab

NCT ID: NCT01096069

Last Updated: 2010-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a correlation between the CD55, CD59, CD35 and CD46 expression on B lymphocytes of patients before and after treatment with rituximab and the level of depletion and repopulation time for these cells. The theoretical rationale of the study assumes that the correlation, if any, will be a negative correlation. However, the hypothesis of positive correlation (two-tailed test) will also be tested.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rituximab, an anti-CD20 monoclonal antibody, is a new alternative treatment for patients with severe immune diseases and resistance to conventional treatment. One of the mechanisms of action of this drug is the complement-mediated lysis. Most RA patients respond well to rituximab treatment, however, some are refractory and mechanism of this non-response is still unclear. The role of CD55 and CD59 protein and its overexpression as a mechanism of resistance to rituximab treatment in lymphoma patients have been investigated. However, there has not been studied a correlation between the intensity of expression of these regulatory molecules on B cells of RA patients and resistance to treatment with Rituximab.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rituximab, rheumatoid arthritis, CD55, CD59

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rituximab

Rheumatoid arthritis patients undergoing treatment with rituximab.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of both gender, aged greater than or equal to 18 years; and lower than 70 years.
2. Patients diagnosed with RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) in 1987 for classification of AR.
3. Patients with a medical indication for therapy with rituximab, with prescription of this therapy for the first time and have not yet received the first dose.
4. DAS28 score greater than or equal to 3.2.
5. Use of adequate contraception, as judged from the attending physician.
6. Desire to participate voluntarily, the ability to understand the protocol, documented by signing the consent form (attached).

Exclusion Criteria

1. overlapping rheumatic disease, autoimmune lymphoproliferative and neoplastic.
2. active infection, patients with the use of cytotoxic drugs, presence of positive serology for HCV, HBV and HIV, active or latent tuberculosis.
3. allergy or hypersensitivity to rituximab.
4. pregnant woman or performing breastfeeding.
5. participating in another clinical study with intervention.
6. with functional class IV defined based on the criteria of Steinbrocker functional classification for RA.
7. prior therapy with Rituximab.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital de Clinicas de Porto Alegre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hospital de Clinicas de Porto Alegre

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ricardo M Xavier, PhD

Role: STUDY_DIRECTOR

HCPA

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ricardo M Xavier, PhD

Role: CONTACT

Phone: 3359-8315

Email: [email protected]

Ana P Alegretti, Master

Role: CONTACT

Phone: 3359-8316

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09/585

Identifier Type: -

Identifier Source: org_study_id